![Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial - Goll - 2019 - Journal of Internal Medicine - Wiley Online Library Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial - Goll - 2019 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/be96bbab-d246-4f1d-9ec2-c9d26cfa5aca/joim12880-toc-0001-m.png)
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial - Goll - 2019 - Journal of Internal Medicine - Wiley Online Library
![Enclosed NOR/NORD/NORDR Switch | Mersen Electrical Power: Fuses, Surge Protective Devices, Cooling & Bus Bars Enclosed NOR/NORD/NORDR Switch | Mersen Electrical Power: Fuses, Surge Protective Devices, Cooling & Bus Bars](https://ep-us.mersen.com/sites/mersen_us/files/styles/cke_image/public/2023-07/Highlight-High-Power-PBD.jpg?itok=rIiE66G9)
Enclosed NOR/NORD/NORDR Switch | Mersen Electrical Power: Fuses, Surge Protective Devices, Cooling & Bus Bars
![Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/fb352f84-2284-441d-9e61-0ab225433e89/gr3.jpg)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial - The Lancet
![Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials | BioDrugs Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials | BioDrugs](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40259-020-00438-7/MediaObjects/40259_2020_438_Fig1_HTML.png)